SEC Info  
  Home     Search     My Interests     Help     Sign In     Please Sign In  

CVS Corp · S-4/A · On 1/16/07

Filed On 1/16/07 5:23pm ET   ·   SEC File 333-139470   ·   Accession Number 950103-7-74

  in   Show  and 
  As Of               Filer                 Filing     As/For/On Docs:Pgs              Issuer               Agent

 1/16/07  CVS Corp                          S-4/A                 10:228                                    Davis Polk & Ward..01/FA

Pre-Effective Amendment to Registration of Securities Issued in a Business-Combination Transaction   ·   Form S-4
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: S-4/A       Pre-Effective Amendment to Registration of          HTML  1,638K 
                          Securities Issued in a                                 
                          Business-Combination Transaction                       
 2: EX-2.3      Plan of Acquisition, Reorganization, Arrangement,   HTML     16K 
                          Liquidation or Succession                              
 3: EX-5.1      Opinion re: Legality                                HTML      9K 
 4: EX-23.1     Consent of Experts or Counsel                       HTML      6K 
 5: EX-23.2     Consent of Experts or Counsel                       HTML      5K 
 6: EX-23.3     Consent of Experts or Counsel                       HTML      6K 
 7: EX-99.1     Miscellaneous Exhibit                               HTML     14K 
 8: EX-99.2     Miscellaneous Exhibit                               HTML     17K 
 9: EX-99.3     Miscellaneous Exhibit                               HTML      7K 
10: EX-99.4     Miscellaneous Exhibit                               HTML      6K 


S-4/A   ·   Pre-Effective Amendment to Registration of Securities Issued in a Business-Combination Transaction

This is an EDGAR HTML document rendered as filed.  [ Alternative Formats ]

S-4/A1st "Page" of 289TOCTopPreviousNextBottomJust 1st
As filed with the Securities and Exchange Commission on January 16, 2007
Registration No. 333-139470


SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

AMENDMENT NO. 2
TO
Form S-4
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933

  CVS CORPORATION  
  (Exact Name of Registrant as Specified in Its Charter)  
     
Delaware 5912 05-0494040
(State or Other Jurisdiction of
Incorporation or Organization)
(Primary Standard Industrial
Classification Code Number)
(I.R.S. Employer
Identification No.)
 
One CVS Drive
Woonsocket, RI 02895
(401) 765-1500
(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)
     
David B. Rickard
Executive Vice President and Chief Financial Officer
CVS Corporation
One CVS Drive
Woonsocket, RI 02895
(401) 765-1500
(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent For Service)

Copies to:
Douglas A. Sgarro, Esq. Louis Goldberg, Esq. Sara J. Finley, Esq. Michael J. O’Brien, Esq.
Executive Vice President-Strategy and John D. Amorosi, Esq. Senior Vice President, Secretary and Tracey A. Zaccone, Esq.
Chief Legal Officer Davis Polk & Wardwell Assistant General Counsel King & Spalding LLP
CVS Corporation 450 Lexington Avenue Caremark Rx, Inc. 1185 Avenue of the Americas
One CVS Drive New York, NY 10017 211 Commerce Street New York, NY 10036
Woonsocket, RI 02895 (212) 450-4000 Suite 800 (212) 556-2100
(401) 765-1500 Nashville, TN 37201
(615) 743-6600
 

     Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement and the effective time of the merger (the “Merger”) of Twain MergerSub Corp., a Delaware corporation formed for the purpose of the Merger and a wholly owned subsidiary of CVS Corporation, a Delaware corporation, with and into Caremark Rx, Inc., as described in the Agreement and Plan of Merger, dated as of November 1, 2006, attached as Annex A to the joint proxy statement/prospectus forming part of this registration statement.
     If the securities being registered on this Form are being offered in connection with the formation of a holding company and there is compliance with General Instruction G, check the following box: o
     If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. o
      If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. o

CALCULATION OF REGISTRATION FEE
Title of Each Class
of Securities To Be Registered
Amount To Be
Registered(1)
Proposed Maximum
Offering Price Per Unit
Proposed Maximum
Aggregate Offering Price(2)
Amount of
Registration Fee(2)
Common Stock, par value $0.01 per share 745,887,633 N/A $22,233,705,898 $2,379,007
(1) Represents the maximum number of shares of common stock, with par value $0.01 per share, of CVS Corporation (“CVS Common Stock”) estimated to be issuable upon completion of the Merger, based on the exchange ratio of 1.670 shares of CVS Common Stock for each share of common stock, par value $0.001 per share, of Caremark Rx, Inc. (“Caremark Common Stock”) (based on 426,541,731 shares of Caremark Common Stock outstanding on December 14, 2006 and 20,097,600 shares of Caremark Common Stock issuable pursuant to the exercise of Caremark options and warrants outstanding on December 14, 2006).
(2)

Previously paid in connection with the initial filing of this registration statement on December 19, 2006. Estimated solely for the purpose of calculating the amount of the registration fee required by Section 6(b) of the Securities Act of 1933 (the “Securities Act”), and calculated pursuant to Rules 457(f)(1) and 457(c) under the Securities Act, the proposed maximum aggregate offering price of the registrant’s common stock was calculated based upon the market value of shares of Caremark Common Stock (the securities to be cancelled in the merger) in accordance with Rule 457(c) under the Securities Act as follows: the product of (1) $49.78 the average of the high and low prices per share of Caremark Common Stock on December 12, 2006 as quoted on the New York Stock Exchange, multiplied by (2) 446,639,331, the sum of the aggregate number of shares of Caremark Common Stock outstanding as of December 14, 2006 and the aggregate number of shares of Caremark Common Stock issuable upon exercise of Caremark options and warrants.

 

     The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.



S-4/A2nd "Page" of 289TOC1stPreviousNextBottomJust 2nd



The information in this joint proxy statement/prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary joint proxy statement/prospectus is not an offer to sell and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.

SUBJECT TO COMPLETION, DATED JANUARY 16, 2007

Image -- cvslogo Image -- caremarklogo

MERGER PROPOSED – YOUR VOTE IS VERY IMPORTANT

The boards of directors of CVS Corporation and Caremark Rx, Inc. have each approved a merger agreement which provides for the combination of the two companies in a transaction structured as a merger of equals. The boards of directors of CVS and Caremark believe that the combination of the two companies will be able to create substantially more long-term stockholder value than either company could individually achieve. Following the completion of the merger, Caremark will be a wholly owned subsidiary of CVS and Caremark stockholders will own approximately 45.5% of the outstanding common stock of the combined company and CVS stockholders will own approximately 54.5% of the outstanding common stock of the combined company, in each case, on a fully diluted basis. CVS Corporation is referred to as CVS and Caremark Rx, Inc. is referred to as Caremark.

The combined company will be named CVS/Caremark Corporation and the shares of the combined company will be traded on the New York Stock Exchange, or the NYSE, under the symbol “CVS”.

If the merger is completed, Caremark’s stockholders will receive 1.670 shares of common stock of CVS/Caremark, for each share of Caremark common stock that they own immediately before the effective time of the merger. Caremark stockholders will receive cash for any fractional shares which they would otherwise receive in the merger. Caremark stockholders will also receive a one-time special cash dividend in the amount of $2.00 per share of Caremark common stock held by each such holder on a record date to be set by the Caremark board of directors, which dividend will be conditioned on the completion of the merger and will be paid at or immediately following the effective time of the merger. CVS stockholders will continue to own their existing shares after the merger. CVS common stock is traded on the NYSE under the symbol “CVS”. On January 12, 2007, the last practicable day before the mailing of this document, the closing price per share of CVS common stock as reported by the NYSE was $31.94.

CVS and Caremark estimate that CVS will issue approximately 712.4 million shares of CVS/Caremark common stock in the merger based on the number of shares of Caremark common stock outstanding on January 15, 2007, and will reserve an additional approximately 33.5 million shares of CVS/Caremark common stock for issuance in connection with CVS/Caremark’s assumption of Caremark’s outstanding options and warrants.

YOUR VOTE IS IMPORTANT. The merger cannot be completed unless, among other things, holders of Caremark common stock vote to adopt the merger agreement and approve the merger, and holders of CVS common stock and CVS Series One ESOP Convertible Preference Stock, voting together as a single class, approve the amendments to CVS’ charter and approve the issuance of CVS/Caremark common stock in the merger.

The CVS board of directors unanimously recommends that CVS stockholders vote “FOR” the amendments to the CVS charter to increase the authorized number of shares and to change the name of CVS to “CVS/Caremark Corporation” and “FOR” the issuance of CVS/Caremark common stock to Caremark stockholders in the merger. The Caremark board of directors unanimously recommends that Caremark stockholders vote “FOR” the adoption of the merger agreement and the approval of the merger.

CVS and Caremark will each hold a special meeting of their respective stockholders to vote on these proposals. Whether or not you plan to attend your company’s special meeting, please take the time to vote by completing and mailing the enclosed proxy card or submitting your proxy by telephone or through the Internet, using the procedures in the proxy voting instructions included with your proxy card. Even if you return the proxy, you may attend the special meeting and vote your shares in person.

This document describes the proposed merger and related transactions in more detail. CVS and Caremark encourage you to read this entire document carefully, including the merger agreement, which is included as Annex A, and the section discussing “Risk Factors” relating to the merger beginning on page 27.

CVS and Caremark look forward to the successful combination of the two companies.



Thomas M. Ryan E. Mac Crawford
Chairman, President and Chief Executive Officer, Chairman, President and Chief Executive Officer,
CVS Corporation Caremark Rx, Inc.

       Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of the merger described in this joint proxy statement/prospectus or the CVS/Caremark common stock to be issued pursuant to the merger or determined if this joint proxy statement/prospectus is accurate or adequate. Any representation to the contrary is a criminal offense.

     This joint proxy statement/prospectus is dated January [•], 2007 and, together with the accompanying proxy card, is first being mailed or otherwise delivered to stockholders of CVS and Caremark on or about [•], 2007.



S-4/A3rd "Page" of 289TOC1stPreviousNextBottomJust 3rd


THIS JOINT PROXY STATEMENT/PROSPECTUS INCORPORATES ADDITIONAL INFORMATION

     This document incorporates by reference important business and financial information about CVS and Caremark from other documents filed with the Securities and Exchange Commission, which is referred to as the SEC, that are not included in or delivered with this joint proxy statement/prospectus. This information is available to you without charge upon your written or oral request. For a list of the documents incorporated by reference into this joint proxy statement/prospectus, see “Where You Can Find More Information” beginning on page 158. You can obtain electronic or hardcopy versions of the documents that are incorporated by reference into this document, without charge, from the Investor Relations section of each company’s website or by requesting them in writing or by telephone as set forth below:

if you are a CVS stockholder:   if you are a Caremark stockholder:
             
Electronic:   www.cvs.com (please see “Financial   Electronic:   www.caremarkrx.com (please see “SEC
    Information” page or “Contact Us”       Filings” page or “Request Document” page
    page in the Investor Relations portion       in the Investor Relations portion of the
    of the site)       site)
             
By Mail:   CVS Corporation   By Mail:   Caremark Rx, Inc.
    One CVS Drive       211 Commerce Street, Suite 800
    Woonsocket, RI 02895       Nashville, TN 37201
    Attention: Investor Relations       Attention: Investor Relations
    E-mail Address: investorinfo@cvs.com       E-mail Address:
            investorinfo@caremark.com
             
By Telephone:   (800) 201-0938   By Telephone:   (800) 633-9509

IF YOU WOULD LIKE TO REQUEST DOCUMENTS, PLEASE DO SO BY FEBRUARY 12, 2007 IN ORDER TO RECEIVE THEM BEFORE YOUR SPECIAL MEETING.

VOTING ELECTRONICALLY, BY TELEPHONE OR BY MAIL

CVS stockholders of record on January 19, 2007 may submit their proxies:

Caremark stockholders of record on January 15, 2007 may submit their proxies:

If you are a beneficial owner, please refer to your proxy card or the information forwarded by your bank, broker or other holder of record to see which options are available to you.



S-4/A4th "Page" of 289TOC1stPreviousNextBottomJust 4th


Image -- cvslogo
NOTICE OF SPECIAL MEETING OF STOCKHOLDERS
To Be Held On February 23, 2007

Dear Stockholder:

     A special meeting of stockholders of CVS Corporation will be held on February 23, 2007 at 11:00 a.m., Eastern Time, at CVS’ corporate headquarters, One CVS Drive, Woonsocket, Rhode Island 02895.

     The purpose of the CVS special meeting is to consider and to vote upon the following proposals:

     The CVS board of directors has unanimously determined that the amendments to the CVS charter and the share issuance are advisable and in the best interests of CVS and its stockholders and recommends that CVS stockholders vote “FOR” the amendments to the CVS charter, “FOR” the issuance of CVS/Caremark common stock to Caremark stockholders in the merger and “FOR” the adjournment or postponement of the special meeting, including if necessary, to solicit additional proxies in favor of the amendments and issuance.

     CVS and Caremark cannot complete the merger unless:

     Your failure to vote will have the same effect as a vote against the approval of the CVS charter amendments and will make it more difficult to obtain the necessary quorum for purposes of approving the share issuance. Therefore, your vote is very important.

     The close of business on January 19, 2007 has been fixed as the record date, which is referred to as the CVS record date, for the determination of CVS stockholders entitled to notice of, and to vote at, the CVS special meeting or any adjournments or postponements of the CVS special meeting. Only holders of CVS common stock and holders of CVS Series One ESOP Convertible Preference Stock of record at the close of business on January 19, 2007 are entitled to notice of, and to vote at, the CVS special meeting or any adjournments or postponements of the CVS special meeting. All CVS Series One ESOP Convertible Preference Stock, which is referred to as the CVS ESOP preference stock, is held by the Bank of New York, as Trustee under the 401(k) Plan and the Employee Stock Ownership Plan of CVS Corporation and Affiliated Companies, which is referred to as the CVS Plan. The CVS Plan consists of both a 401(k) Plan and an Employee Stock Ownership Plan. Each participant in the CVS Plan instructs the trustee of the CVS Plan how to vote his or her shares of (i) CVS ESOP preference stock and (ii) CVS common stock held in the CVS Plan. Unallocated shares of CVS ESOP preference stock and CVS common stock held in the CVS Plan and shares of CVS ESOP preference stock and CVS common stock held in the CVS Plan with respect to which the trustee of the CVS Plan receives no timely voting instructions will be voted by the trustee of the CVS Plan in the same proportion as it votes all the shares as to which such trustee has received timely voting instructions. A list of the holders of CVS common stock entitled to vote at the CVS special meeting will be available for examination by any CVS stockholder, for any purpose germane to the CVS special meeting, at CVS’ principal executive offices at One CVS Drive, Woonsocket, Rhode Island 02895, for ten days before the CVS special meeting, between the hours of 9:00 a.m. and 3:00 p.m., and at the CVS special meeting during the entire time of the meeting.



S-4/A5th "Page" of 289TOC1stPreviousNextBottomJust 5th


     We direct your attention to the joint proxy statement/prospectus accompanying this notice for a more complete statement regarding the matters proposed to be acted upon at the meeting. We encourage you to read the entire joint proxy statement/prospectus carefully, including the merger agreement, which is included as Annex A to the joint proxy statement/prospectus, and the section discussing “Risk Factors” beginning on page 27.

     SO THAT YOUR SHARES WILL BE REPRESENTED WHETHER OR NOT YOU ATTEND THE CVS SPECIAL MEETING, PLEASE VOTE AS SOON AS POSSIBLE BY MAIL, BY TELEPHONE OR THROUGH THE INTERNET. INSTRUCTIONS ON THESE DIFFERENT WAYS TO VOTE YOUR PROXY ARE FOUND ON THE ENCLOSED WHITE PROXY FORM. YOU MAY REVOKE YOUR PROXY AT ANY TIME BEFORE IT IS VOTED AT THE CVS SPECIAL MEETING. REMEMBER, YOUR VOTE IS IMPORTANT, SO PLEASE ACT TODAY!

By Order of the Board of Directors,
 
Thomas M. Ryan
Chairman, President and Chief Executive Officer

January __, 2007



S-4/A6th "Page" of 289TOC1stPreviousNextBottomJust 6th


Image -- caremarklogo

NOTICE OF SPECIAL MEETING OF STOCKHOLDERS
To Be Held On
February 20, 2007

Dear Caremark Stockholder:

     Caremark is pleased to invite you to attend a special meeting of the stockholders of Caremark Rx, Inc. which will be held on February 20, 2007 at 1:00 p.m., Central Time, at the Hilton Nashville Downtown at 121 Fourth Avenue South, Nashville, Tennessee 37201.

     The purpose of the Caremark special meeting is to consider and to vote upon the following proposals:

     The Caremark board of directors has unanimously determined that the merger agreement and the transactions contemplated by it, including the merger, are advisable and in the best interests of Caremark and its stockholders, unanimously approved and adopted the merger agreement and the transactions contemplated by it, including the merger, and recommends that the Caremark stockholders vote “FOR” the adoption of the merger agreement and the approval of the merger and “FOR” the adjournment or postponement of the Caremark special meeting, including if necessary, to solicit additional proxies in favor of such adoption and approval.

     CVS and Caremark cannot complete the merger unless the proposal to adopt the merger agreement and to approve the merger is approved by holders of a majority of the outstanding shares of Caremark common stock entitled to vote at the Caremark special meeting.

     Your failure to vote will have the same effect as a vote against the adoption of the merger agreement and the approval of the merger. Therefore, your vote is very important.

     The close of business on January 15, 2007 has been fixed as the record date, which is referred to as the Caremark record date, for the determination of Caremark stockholders entitled to notice of, and to vote at, the Caremark special meeting or any adjournments or postponements of the Caremark special meeting. Only holders of record of Caremark common stock at the close of business on the Caremark record date are entitled to notice of, and to vote at, the Caremark special meeting. A complete list of stockholders entitled to vote at the Caremark special meeting will be available for examination by any of Caremark’s stockholders at Caremark’s headquarters at 211 Commerce Street, Suite 800, Nashville, Tennessee 37201 for purposes pertaining to the Caremark special meeting, during normal business hours, for a period of 10 days before the Caremark special meeting, and at the time and place of the Caremark special meeting.

     We direct your attention to the joint proxy statement/prospectus accompanying this notice for more detailed information regarding the matters proposed to be acted upon at the Caremark special meeting. You are encouraged to read the entire joint proxy statement/prospectus carefully, including the merger agreement, which is included as Annex A to the joint proxy statement/prospectus, and “Risk Factors” beginning on page 27 of the joint proxy statement/prospectus.

     SO THAT YOUR SHARES WILL BE REPRESENTED WHETHER OR NOT YOU ATTEND THE CAREMARK SPECIAL MEETING, PLEASE VOTE AS SOON AS POSSIBLE BY (1) ACCESSING THE INTERNET WEBSITE SPECIFIED ON YOUR WHITE PROXY CARD; (2) CALLING THE TOLL-FREE NUMBER SPECIFIED ON YOUR WHITE PROXY CARD; OR (3) SIGNING, DATING AND MAILING THE ENCLOSED WHITE PROXY CARD SO THAT YOUR SHARES MAY BE REPRESENTED AT THE CAREMARK SPECIAL MEETING. YOU MAY REVOKE YOUR PROXY AT ANY TIME BEFORE IT IS VOTED AT THE CAREMARK SPECIAL MEETING BY FOLLOWING THE PROCEDURES SET FORTH IN THE ACCOMPANYING JOINT PROXY STATEMENT/PROSPECTUS. REMEMBER, YOUR VOTE IS IMPORTANT, SO PLEASE ACT PROMPTLY.

By Order of the Board of Directors,
 
E. Mac Crawford
Chairman, President and Chief Executive Officer

January __, 2007



S-4/A7th "Page" of 289TOC1stPreviousNextBottomJust 7th


TABLE OF CONTENTS


     
Page   Page
QUESTIONS AND ANSWERS ABOUT THE                No Appraisal Rights   96
         MERGER   1            Caremark Warrants   97
SUMMARY   7            Merger-Related Litigation   97
         The Companies   7   MATERIAL FEDERAL INCOME TAX    
         The Merger   8            CONSEQUENCES OF THE SPECIAL CASH
SELECTED HISTORICAL CONSOLIDATED                DIVIDEND AND THE MERGER   99
         FINANCIAL DATA OF CVS   20            General   99
SELECTED HISTORICAL CONSOLIDATED                U.S. Federal Income Tax Consequences to    
         FINANCIAL DATA OF CAREMARK   22                      Caremark Stockholders   100
SUMMARY UNAUDITED PRO FORMA                U.S. Federal Income Tax Consequences to    
         FINANCIAL DATA   23                      CVS Stockholders   101
COMPARATIVE PER SHARE INFORMATION   24   REGULATORY AND OTHER APPROVALS    
COMPARATIVE PER SHARE MARKET PRICE                REQUIRED FOR THE MERGER   102
         AND DIVIDEND INFORMATION   25            U.S. Antitrust Filing   102
RISK FACTORS   27   THE COMPANIES   104
         Risks Related to the Merger   27            CVS   104
         Risks Related to CVS, Caremark and the                Caremark   104
                   Combined Company   31   THE MERGER AGREEMENT   106
CAUTIONARY STATEMENT REGARDING                Explanatory Note Regarding Summary of    
         FORWARD-LOOKING STATEMENTS   38                 Merger Agreement and Representations    
THE MERGER   40                 and Warranties in the Merger Agreement   106
         Structure of the Merger   40            Structure of the Merger   106
         Merger Consideration   40            Timing of Closing   106
         Caremark Special Cash Dividend   40            Merger Consideration   106
                 Exchange of Shares   107
         Accelerated Share Repurchase Transaction   40            Fractional Shares   107
         Background of the Merger   40            Caremark Stock Options   107
         Rationale for the Merger   51            Listing of CVS/Caremark Stock   108
         CVS Reasons for the Merger   53            CVS Governance and Related Matters   108
         Recommendations of the CVS Board of                Representations and Warranties   108
                   Directors   55            Certain Covenants   110
         CVS Projections   56            Conditions to Completion of the Merger   114
         Opinions of Financial Advisors to the CVS                Termination   115
                   Board of Directors   56            Termination Fees   116
         Interests of CVS Executive Officers and                Other Expenses   117
                   Directors in the Merger   74            Amendments; Waivers   117
         Caremark Reasons for the Merger   75   THE CVS SPECIAL MEETING   118
         Recommendations of the Caremark Board of                Date, Time and Place   118
                   Directors   79            Purpose of the CVS Special Meeting   118
         Caremark Projections   79            Board Recommendations   118
         Opinions of Financial Advisors to Caremark   80            CVS Record Date; Shares Entitled to Vote   118
         Interests of Caremark Executive Officers and                Quorum Requirement   119
                   Directors in the Merger   86            Stock Ownership of CVS Executive Officers    
         Accounting Treatment   95                 and Directors   119
         Board of Directors and Management of                Votes Required to Approve CVS Proposals   120
                   CVS/Caremark Following the Merger;                Voting of Proxies   120
                   Headquarters   95            Revocation of Proxies   121
         Repurchases of Caremark Common Stock   96            Solicitation of Proxies   122
         Federal Securities Laws Consequences; Stock                Householding   122
                   Transfer Restriction Agreements   96   THE CAREMARK SPECIAL MEETING   123

i




S-4/A8th "Page" of 289TOC1stPreviousNextBottomJust 8th


         Date, Time and Place   123   DESCRIPTION OF CVS CAPITAL STOCK   130
         Purpose of the Caremark Special Meeting   123            Authorized Capital Stock   130
         Board Recommendations   123            CVS Common Stock   130
         Caremark Record Date; Shares Entitled to                CVS Preferred Stock and Preference Stock   131
              Vote   123            Transfer Agent and Registrar   132
         Quorum Requirement   123            Stock Exchange Listing; Delisting and    
         Stock Ownership of Caremark Executive                     Deregistration of Caremark Common    
              Officers and Directors   124                 Stock   132
         Votes Required to Approve Caremark       COMPARISON OF STOCKHOLDER RIGHTS   133
              Proposals   124   UNAUDITED PRO FORMA CONDENSED    
         Voting of Proxies   124            COMBINED FINANCIAL INFORMATION   148
         Revocation of Proxies   125            Notes to Unaudited Pro Forma Condensed    
         Solicitation of Proxies   126                 Combined Financial Statements   152
         Householding   126   LEGAL MATTERS   157
CVS CHARTER AMENDMENT   127   INDEPENDENT REGISTERED PUBLIC    
         Increase of Authorized Common Stock   127            ACCOUNTING FIRM   157
         Name Change   127   FUTURE STOCKHOLDER PROPOSALS   157
CVS BYLAWS AMENDMENT   128            CVS   157
         Corporate Governance   128            Caremark   158
         Chairman of the Board   128   WHERE YOU CAN FIND MORE    
         Chief Executive Officer   128            INFORMATION   158
         Headquarters   129   PART II INFORMATION NOT REQUIRED IN    
         Other Changes to Bylaws   129            PROSPECTUS   II-1
         Amendments   129        

LIST OF ANNEXES
         Annex A   Agreement and Plan of Merger
         Annex B   CVS Charter Amendment
         Annex C   Amended and Restated CVS Bylaws
         Annex D   Opinion of Evercore Group L.L.C.
         Annex E   Opinion of Lehman Brothers Inc.
         Annex F   Opinion of UBS Securities LLC
         Annex G   Opinion of J.P. Morgan Securities Inc.

ii




S-4/A9th "Page" of 289TOC1stPreviousNextBottomJust 9th


QUESTIONS AND ANSWERS ABOUT THE MERGER

Q:      What will happen in the transaction?
 
A:      CVS and Caremark are proposing to combine the two companies in a merger of equals transaction. In the merger, Caremark will be merged with and into a wholly owned subsidiary of CVS that was formed for the purpose of the merger with the CVS subsidiary surviving the merger and remaining a wholly owned subsidiary of CVS. Immediately following the merger, CVS Corporation will be renamed “CVS/Caremark Corporation” and Twain MergerSub LLC will be renamed “Caremark Rx, L.L.C.”. Caremark stockholders will have their shares of Caremark common stock converted into newly issued shares of common stock of CVS/Caremark Corporation, and CVS stockholders will retain their existing shares of CVS common stock and CVS Series One ESOP Convertible Preference Stock, which is referred to as CVS ESOP preference stock. CVS and Caremark expect that, upon completion of the merger, approximately 45.5% of the outstanding common stock of the combined company on a fully diluted basis will be held by former Caremark stockholders, and approximately 54.5% of the outstanding common stock of the combined company on a fully diluted basis will be held by former CVS stockholders.
 
  In the merger, CVS’ Amended and Restated Certificate of Incorporation, which is referred to as the CVS charter, will be amended to increase the number of authorized shares of CVS common stock from 1 billion to 3.2 billion and to change CVS’ name to CVS/Caremark Corporation. These changes are described under the section entitled “CVS Charter Amendment” beginning on page 127.
 
Q:      What will I receive in the merger?
 
A:      CVS Stockholders. Each share of CVS common stock and CVS ESOP preference stock held by CVS stockholders immediately before the merger will continue to represent one share of CVS/Caremark common stock and one share of ESOP preference stock of the combined company, as applicable, after the effective time of the merger. In other words, CVS stockholders will receive no consideration in the merger.
 
  Caremark Stockholders. For each share of Caremark common stock held, Caremark stockholders will have the right to receive 1.670 shares of CVS/Caremark common stock. At the effective time of the merger, each share of Caremark common stock will be cancelled and converted automatically into the right to receive 1.670 shares of CVS/Caremark common stock. Caremark stockholders will receive cash for any fractional shares of CVS/Caremark common stock that they would otherwise receive in the merger. The amount of cash for fractional shares will be calculated by multiplying the fraction of a share of CVS/Caremark common stock to which the Caremark stockholder would be entitled to receive in the merger by the closing sale price of a share of CVS/Caremark common stock on the first trading day immediately following the effective time of the merger.
 
Q:      Will I receive the Caremark special cash dividend?
 
A:      CVS has granted a waiver to Caremark from the restrictions set forth in the merger agreement to permit Caremark to pay a one-time, special cash dividend to holders of Caremark common stock (on a record date to be set by the Caremark board of directors) in the amount of $2.00 per share of Caremark common stock held by each such holder on such record date, which dividend shall be declared prior to the Caremark special meeting, but shall only become payable upon or after the effective time of the merger, and such payment shall be conditioned upon the completion of the merger. You can find further details regarding this dividend in the section entitled “The Merger—Caremark Special Cash Dividend” beginning on page 40.
 
Q:      What is the accelerated share repurchase transaction?
 
A:      CVS and Caremark have agreed that as promptly as practicable after the closing of the merger, CVS/Caremark will execute an accelerated share repurchase transaction on customary terms, whereby CVS/Caremark will retire 150 million shares of its common stock (approximately 9.8% of the combined company’s pro-forma outstanding shares after giving effect to the merger). To implement this transaction, CVS/Caremark will enter into an agreement with one or more financial institutions to purchase shares of common stock from each of them and pay each of them for the shares to be retired. The effect of this transaction and the related borrowing by the combined
 



S-4/A10th "Page" of 289TOC1stPreviousNextBottomJust 10th


  company to finance the transaction will be the immediate reduction of shares outstanding by 150 million shares and an increase in the combined company’s funded debt by approximately $4.8 billion. CVS has received commitments for such financing. It is anticipated that the agreement with the financial institutions will provide for a purchase price adjustment mechanism customary for such a transaction. The purchase price adjustment under such agreement may be subject to limits on the amounts that may be owed by CVS/Caremark or the financial institutions or both.
 
Q:      When and where are the CVS and Caremark special meetings?
 
A:      CVS Special Meeting. A special meeting of CVS stockholders, which is referred to as the CVS special meeting, will be held on February 23, 2007 at 11:00 a.m., Eastern Time, at CVS’ corporate headquarters, One CVS Drive, Woonsocket, Rhode Island 02895, to consider and vote on proposals related to the merger.
 
  Caremark Special Meeting. A special meeting of Caremark stockholders, which is referred to as the Caremark special meeting, will be held on February 20, 2007 at 1:00 p.m., Central Time, at the Hilton Nashville Downtown at 121 Fourth Avenue South, Nashville, Tennessee 37201 to consider and vote on proposals related to the merger.
 
Q:      What stockholder votes are required?
 
A:      CVS stockholders are being asked to approve two separate proposals that are necessary to complete the merger. The completion of the merger requires:
 
 
  • the approval of the amendments to the CVS charter by holders of CVS common stock and CVS ESOP preference stock, voting together as a single class, representing a majority of the votes entitled to be cast by such holders on the proposal; and
     
     
  • the approval of the issuance of shares of CVS/Caremark common stock to Caremark stockholders in the merger by holders of CVS common stock and CVS ESOP preference stock, voting together as a single class, representing a majority of the votes cast in person or by proxy at the CVS special meeting, provided that the total number of votes cast on the proposal represents over 50% of the total number of votes entitled to be cast by holders of the outstanding CVS common stock and CVS ESOP preference stock, voting together as a single class, which is referred to as the 50% “vote cast” quorum requirement.
     
      The CVS board of directors recommends that CVS stockholders vote “FOR” the amendments of the CVS charter to increase the number of authorized shares of CVS common stock and to rename the combined company CVS/Caremark Corporation and “FOR” the issuance of CVS/Caremark common stock in connection with the merger.
     
      Caremark stockholders are being asked to adopt the merger agreement and approve the merger, which requires the approval of holders of a majority of the outstanding shares of Caremark common stock entitled to vote at the Caremark special meeting.
     
      The Caremark board of directors recommends that Caremark stockholders vote “FOR” the adoption of the merger agreement and approval of the merger.
     
    Q:      Why is my vote important?
     
    A:      In order to complete the merger, Caremark stockholders must adopt the merger agreement and approve the merger, and CVS stockholders must approve the issuance of CVS/Caremark common stock to Caremark stockholders in the merger and the amendments to the CVS charter to increase the number of authorized shares of CVS common stock and to rename the combined company CVS/Caremark Corporation.
     
      If you are a CVS stockholder and you abstain from voting or do not vote (either in person or by proxy), or fail to direct your broker how to vote, it will have the same effect as a vote “AGAINST” the proposal to approve the amendments to the CVS charter. If you abstain or do not vote (either in person or by proxy), or fail to direct your broker how to vote, it will have no effect in determining whether the issuance of shares of CVS/Caremark common stock to Caremark stockholders in the merger will be approved, but will not be
     

    2




    S-4/A11th "Page" of 289TOC1stPreviousNextBottomJust 11th


      considered to be a “vote cast” for purposes of this proposal, making it more difficult to satisfy the 50% “vote cast” quorum requirement for the proposal.
     
      If you are a Caremark stockholder and you abstain from voting or do not vote (either in person or by proxy), or fail to direct your broker how to vote, it will have the same effect as a vote “AGAINST” the proposal to adopt the merger agreement and to approve the merger.
     
    Q:      Are the issuance of CVS/Caremark common stock in the merger and the CVS charter amendments each conditioned upon each other?
     
    A:      Yes. The proposal to amend the CVS charter and the proposal to issue shares of CVS/Caremark common stock to Caremark stockholders in the merger are each conditioned upon the approval of the other and the approval of each such proposal is a condition to completion of the merger. Neither the issuance of CVS/Caremark common stock in connection with the merger nor the amendments of the CVS charter will take place unless both of these proposals are approved by the CVS stockholders and the merger is completed. Therefore, the completion of the merger cannot proceed without the approval of both proposals.
     
    Q:      What do I do if I want to change my vote?
     
    A:      You can change your vote at any time before your proxy is voted at your stockholders’ meeting. You can do this in one of four ways:
     
     
  • you can send a signed notice of revocation;
     
     
  • you can grant a new, valid proxy bearing a later date;
     
     
  • you can vote again by telephone or through the Internet; or
     
     
  • if you are a holder of record, you can attend the applicable special meeting and vote in person, but your attendance alone will not revoke any proxy that you have previously given.
     
      If you choose either of the first two methods, you must send your notice of revocation or your new proxy to your company’s Corporate Secretary at the address under “The Companies” beginning on page 104 no later than the beginning of the applicable special meeting. If you are a CVS stockholder, you can find further details on how to revoke your proxy in “The CVS Special Meeting—Revocation of Proxies” beginning on page 121. If you are a Caremark stockholder, you can find further details on how to revoke your proxy in “The Caremark Special Meeting—Revocation of Proxies” beginning on page 125.
     
    Q:      If my shares are held in “street name” by my broker, will my broker vote my shares for me?
     
    A:      No. Your broker is not permitted to decide how your shares should be voted. Your broker will only vote your shares on a proposal if you provide your broker with voting instructions on that proposal. You should instruct your broker to vote your shares by following the directions that your broker provides you. Please check the voting information form used by your broker to see if it offers telephone or Internet voting.
     
      A broker non-vote occurs when a beneficial owner fails to provide voting instructions to his or her broker as to how to vote the shares held by the broker in street name and the broker does not have discretionary authority to vote without instructions. Brokers do not have discretionary authority to vote on any of the Caremark proposals or CVS proposals. By signing your proxy card and returning it to your broker without specific instructions as to any proposal, your shares represented by that proxy will be voted in favor of that proposal. Any shares you beneficially own not identified as represented by that proxy will be considered broker non- votes. See “The CVS Special Meeting” beginning on page 118 and The Caremark Special Meeting beginning on page 123.
     
    Q:      What if I fail to instruct my broker with respect to those items that are necessary to consummate the merger?
     
    A:      If you are a CVS stockholder:
     

    3




    S-4/A12th "Page" of 289TOC1stPreviousNextBottomJust 12th


     
  • with respect to the proposal to amend the CVS charter, a broker non-vote will be counted towards a quorum at the CVS special meeting, but will have the same effect as a vote “AGAINST” the proposal to amend the CVS charter; and
     
     
  • with respect to the proposal to issue shares of CVS/Caremark common stock to Caremark stockholders in the merger, a broker non-vote will not be considered a “vote cast” for purposes of satisfying the applicable quorum requirement, making it more difficult to obtain the necessary quorum. However, if the quorum requirement is satisfied, a broker non-vote will have no effect on the proposal to issue shares of CVS/Caremark common stock to Caremark stockholders in the merger.
     
      If you are a Caremark stockholder, a broker non-vote will be counted towards a quorum at the Caremark special meeting, but will have the same effect as a vote “AGAINST” the proposal to adopt the merger agreement and approve the merger.
     
      For additional information, see “The CVS Special Meeting—Votes Required to Approve CVS Proposals” beginning on page 120 if you are a CVS stockholder, and “The Caremark Special Meeting—Votes Required to Approve Caremark Proposals” beginning on page 124 if you are a Caremark stockholder.
     
    Q:      What do I do now?
     
    A:      Carefully read and consider the information contained in and incorporated by reference into this document, including its annexes.
     
      In order for your shares to be represented at your stockholders’ meeting:
     
     
  • you can vote by telephone or through the Internet by following the instructions included on your WHITE proxy card;
     
     
  • you can indicate on the enclosed WHITE proxy card how you would like to vote and sign and return the proxy card in the accompanying pre-addressed postage paid envelope; or
     
     
  • you can attend your special meeting in person.
     
    Q:      Should I send in my stock certificates now?
     
    A:      No. Caremark stockholders should not send in their stock certificates at this time. If the merger proceeds, CVS’ exchange agent will send former Caremark stockholders a letter of transmittal explaining what they must do to exchange their Caremark stock certificates or trans